MDY Mdy Healthcare

RNS No 5773c
MEDISYS PLC
4th March 1999


  DISTRIBUTION AGREEMENT SIGNED WITH LABORATOIRE VERMED FOLLOWING APPROVAL
                       FROM FRENCH MINISTRY OF HEALTH

Medisys PLC announces today that its medical diagnostics division,
Hypoguard, has entered into a distribution agreement with Laboratoire
Vermed, the French medical distributor, for the exclusive distribution of
the Supreme Glucose Monitoring System in the French market.  This follows
approval of the system from the French Ministry of Health.

Since the acquisition of Hypoguard by Medisys almost two years ago, the
Company has rapidly developed new and improved point-of-care products for
diabetics utilising existing and newly developed technology.  The Supreme
System, which includes a metered system (the Supreme Petit) and a visual
system (the Spectrum) is one of only nine systems approved for use in
France.  In addition, the Spectrum is the first of these products to enter
the market and incorporates a proprietary non-wipe system which is easier
for diabetics to use compared to traditional systems.

There are approximately three million diabetics in France, each of whom
needs daily monitoring of their blood glucose levels.  The percentage of the
population suffering from this disease is increasing as a result of Western
lifestyle and diet.  The Supreme product, due to its ease of use and
accuracy, is a significant step forward in helping diabetics to lead as
normal a life as possible, while maintaining control over their condition.

Kurt Amundson, President and Chief Operating Officer of Medisys, said:

"We are very pleased to receive approval of the Supreme system and are
delighted to enter into this distribution agreement with a highly respected
company such as Vermed.  This represents the first major commercial
recognition of the innovative Spectrum product and we believe that it
represents the achievement of a major milestone for Hypoguard and supports
the Group's growth strategy.  We are optimistic that it will achieve
significant market share in the French market for products used in the
monitoring and treatment of diabetes and we have recently received and
shipped our first order under the distribution agreement."

Medisys PLC is a leading developer of point-of-care diagnostic products for
use in the diagnosis and treatment of many diseases including diabetes.  The
Company also develops and distributes various medical safety products and
sutures through its Lukens Medical division.

Enquiries:

Medisys PLC                                  Tel: 001 650 327 7900
Kurt Amundson, President & Chief Operating Officer

Gavin Anderson & Company                     Tel: 0171 457 2345
David Yates/Sophie Pender-Cudlip


END

MSCMLGGFKDNLLMM

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jul 2023 bis Jul 2024